AU2002361198B2 - 5HT4 partial agonist pharmaceutical compositions - Google Patents

5HT4 partial agonist pharmaceutical compositions Download PDF

Info

Publication number
AU2002361198B2
AU2002361198B2 AU2002361198A AU2002361198A AU2002361198B2 AU 2002361198 B2 AU2002361198 B2 AU 2002361198B2 AU 2002361198 A AU2002361198 A AU 2002361198A AU 2002361198 A AU2002361198 A AU 2002361198A AU 2002361198 B2 AU2002361198 B2 AU 2002361198B2
Authority
AU
Australia
Prior art keywords
composition according
tegaserod
mixture
disintegrant
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002361198A
Other languages
English (en)
Other versions
AU2002361198A1 (en
Inventor
Jerome Aubert
Christian Vitzling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2002361198A1 publication Critical patent/AU2002361198A1/en
Application granted granted Critical
Publication of AU2002361198B2 publication Critical patent/AU2002361198B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002361198A 2001-12-21 2002-12-20 5HT4 partial agonist pharmaceutical compositions Ceased AU2002361198B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod
EP01403339.3 2001-12-21
PCT/EP2002/014674 WO2003053432A1 (en) 2001-12-21 2002-12-20 5ht4 partial agonist pharmaceutical compositions

Publications (2)

Publication Number Publication Date
AU2002361198A1 AU2002361198A1 (en) 2003-07-09
AU2002361198B2 true AU2002361198B2 (en) 2006-06-08

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002361198A Ceased AU2002361198B2 (en) 2001-12-21 2002-12-20 5HT4 partial agonist pharmaceutical compositions

Country Status (31)

Country Link
US (2) US20050106236A1 (https=)
EP (2) EP1321142A1 (https=)
JP (1) JP4718776B2 (https=)
KR (1) KR100980144B1 (https=)
CN (1) CN100464749C (https=)
AR (1) AR037937A1 (https=)
AT (1) ATE320807T1 (https=)
AU (1) AU2002361198B2 (https=)
BR (1) BR0215148A (https=)
CA (1) CA2470668C (https=)
CO (1) CO5640102A2 (https=)
CY (1) CY1105559T1 (https=)
DE (1) DE60210139T2 (https=)
DK (1) DK1458377T3 (https=)
EC (1) ECSP105163A (https=)
EG (1) EG24194A (https=)
ES (1) ES2258171T3 (https=)
HU (1) HU226589B1 (https=)
IL (2) IL162451A0 (https=)
MX (1) MXPA04006157A (https=)
MY (1) MY139546A (https=)
NO (1) NO20042779L (https=)
NZ (1) NZ533585A (https=)
PE (1) PE20030872A1 (https=)
PL (1) PL369509A1 (https=)
PT (1) PT1458377E (https=)
RU (1) RU2322978C2 (https=)
SI (1) SI1458377T1 (https=)
TW (1) TWI260221B (https=)
WO (1) WO2003053432A1 (https=)
ZA (1) ZA200404467B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1314185B1 (it) * 1998-08-21 2002-12-06 Novartis Ag Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
SG168407A1 (en) 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050119328A1 (en) * 2003-03-25 2005-06-02 Hetero Drugs Limited Novel crysalline forms of tegaserod maleate
EP1629280A2 (en) * 2003-05-21 2006-03-01 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
AR045081A1 (es) * 2003-07-24 2005-10-12 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
ES2655435T3 (es) 2003-09-12 2018-02-20 Amgen Inc. Formulación de disolución rápida de cinacalcet
KR20060111675A (ko) * 2003-12-16 2006-10-27 테바 파마슈티컬 인더스트리즈 리미티드 테가세로드 염기 및 그것의 염의 다형태
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
SI2384318T1 (en) 2008-12-31 2018-03-30 Ardelyx, Inc. MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
LT2983667T (lt) 2013-04-12 2019-07-10 Ardelyx, Inc. Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
CA3049678A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010526A2 (en) * 1998-08-21 2000-03-02 Novartis Ag New oral formulation for 5-ht4 agonists or antagonists
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
EA004872B1 (ru) * 1999-08-03 2004-08-26 ЛИЛЛИ АЙКОС эЛ-эЛ-Си β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010526A2 (en) * 1998-08-21 2000-03-02 Novartis Ag New oral formulation for 5-ht4 agonists or antagonists
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration

Also Published As

Publication number Publication date
BR0215148A (pt) 2004-10-19
US20090104263A1 (en) 2009-04-23
DK1458377T3 (da) 2006-06-12
IL162451A (en) 2009-02-11
EP1321142A1 (en) 2003-06-25
WO2003053432A1 (en) 2003-07-03
AU2002361198A1 (en) 2003-07-09
JP2005516946A (ja) 2005-06-09
CA2470668A1 (en) 2003-07-03
DE60210139T2 (de) 2006-08-17
IL162451A0 (en) 2005-11-20
KR20040066922A (ko) 2004-07-27
PE20030872A1 (es) 2003-11-24
CO5640102A2 (es) 2006-05-31
HU226589B1 (en) 2009-04-28
ATE320807T1 (de) 2006-04-15
NZ533585A (en) 2006-04-28
RU2322978C2 (ru) 2008-04-27
ZA200404467B (en) 2006-05-31
RU2004122631A (ru) 2005-08-10
MY139546A (en) 2009-10-30
CN1606438A (zh) 2005-04-13
HUP0402492A3 (en) 2008-04-28
TWI260221B (en) 2006-08-21
AR037937A1 (es) 2004-12-22
SI1458377T1 (sl) 2006-08-31
TW200410684A (en) 2004-07-01
JP4718776B2 (ja) 2011-07-06
ES2258171T3 (es) 2006-08-16
EP1458377A1 (en) 2004-09-22
CN100464749C (zh) 2009-03-04
CY1105559T1 (el) 2010-07-28
EG24194A (en) 2008-10-14
US20050106236A1 (en) 2005-05-19
PL369509A1 (en) 2005-04-18
NO20042779L (no) 2004-09-17
CA2470668C (en) 2011-07-05
MXPA04006157A (es) 2004-10-27
HUP0402492A2 (hu) 2005-07-28
EP1458377B1 (en) 2006-03-22
ECSP105163A (es) 2010-07-30
PT1458377E (pt) 2006-07-31
KR100980144B1 (ko) 2010-09-03
DE60210139D1 (de) 2006-05-11

Similar Documents

Publication Publication Date Title
AU2002361198B2 (en) 5HT4 partial agonist pharmaceutical compositions
EP1058538B9 (en) Fast disintegrating tablets
KR100970665B1 (ko) 알푸조신 또는 그의 염을 함유하는 서방성 정제
US6599530B2 (en) Oral compacted composition comprising catechol derivatives
KR19990071505A (ko) 약학 제제
BG107372A (bg) Препарати със забавено действие на хинолонови антибиотици и метод за получаването им
NZ532829A (en) Film coated solid pharmaceutical compositions comprising sumatriptin for treating pain
JPH0757726B2 (ja) 高分子量ヒドロキシプロピルメチルセルロースを基剤にした徐放性錠剤
HU200924B (en) Process for producing pharmaceutical compositions comprising terfenadine
AU2005256653B2 (en) Oral sustained release formulation of tedisamil with gastric retention properties
EP0266707B1 (en) Sustained release labetalol tablet
US4940580A (en) Sustained release labetalol tablets
AU2002333235B2 (en) Pharmaceutical formulation containing an LTB4 antagonist
WO2005092293A1 (en) Formulations of metformin
US20070160667A1 (en) Controlled release formulation of divalproex sodium
US20030229101A1 (en) Tablets comprising ciprofloxacin hydrochloride
EP2340813A1 (en) Solid dosage formulations of galantamine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired